glp 1 covered by blue cross blue shield of Michigan won't cover popular weight-loss drugs BCBS returns to profit after

3.2 Combination Therapy The heterogeneity of cancer metabolism, even within the same tumor [62], poses many challenges for potential drug therapies

Dont risk it

Adv Anat Pathol

A new retrospective study from UCLA, published in ACR Open Rheumatology , suggests that GLP-1 RAs such as semaglutide and tirzepatide not only lower body weight and improve metabolic health, but also reduce RA disease activity and patient-reported pain

This is concerning because loss of skeletal muscle can lead to decreased strength, reduced functional capacity, and a lower resting metabolic rate, potentially making weight regain more likely after medication discontinuation

Ferroptosis in organ fibrosis diseases Following acute and chronic injury, the uncontrolled regulation of inflammation in tissues causes excessive ECM deposition and fibrosis, which irreversibly destroys the structure and function of tissues and organs, resulting in organ failure and high mortality [5]